Meeting
2021 ASCO Annual Meeting
Impact of rapid multigene assays with short turnaround time (TAT) on the development of precision medicine for non-small cell lung cancer (NSCLC).
Authors
Shingo Matsumoto
National Cancer Center Hospital East, Kashiwa, Japan
Shingo Matsumoto , Takaya Ikeda , Kiyotaka Yoh , Akira Sugimoto , Terufumi Kato , Kei Kunimasa , Atsushi Nakamura , Ichiro Nakachi , Shoichi Kuyama , Jun Sakakibara-Konishi , Haruko Daga , Eiji Iwama , Kageaki Taima , Naoki Furuya , Kaname Nosaki , Hiroki Izumi , Yoshitaka Zenke , Koichi Goto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9094)
DOI
10.1200/JCO.2021.39.15_suppl.9094
Abstract #
9094
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Establishment of the first international large-scale, genomic screening platform to identify patients with rare oncogene drivers in non-small cell lung cancer (NSCLC) in East Asia.
First Author: Shingo Matsumoto
Poster
2018 ASCO Annual Meeting
Contribution of nationwide genome screening in Japan (LC-SCRUM-Japan) to the development of precision medicine for non-small cell lung cancer.
First Author: Takashi Seto
Poster
2016 ASCO Annual Meeting
Development of nationwide genomic screening project (LC-SCRUM-Japan) contributing to the establishment of precision medicine in Japan.
First Author: Takuma Yokoyama
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox